Title: Radium-223 for the treatment of prostate cancer
Abstract: Introduction: Bone metastases cause significant morbidity and mortality in castration-resistant prostate cancer (CRPC). Until recently, treatment options have been limited, but now six drugs are known to extend life expectancy, with docetaxel the current standard first-line cytotoxic therapy. Phase III studies have also shown a survival advantage for sipuleucel-T, cabazitaxel, abiraterone, enzalutamide and radium-223. Radium-223 is unique among these agents, as the only bone-directed therapy shown to prolong survival in CRPC.
Publication Year: 2013
Publication Date: 2013-01-15
Language: en
Type: review
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 16
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot